Yan Han, Female, Han Nationality, born in Shenyang of Liaoning Province in June 1979, a Master’s Degree in Clinical Pharmacology and senior experimentalist. Now, she holds the post of the Director of Pharma-toxicology Laboratory of Shanghai Institute of Planned Parenthood Research (SIPPR) and the Quality Assurance Department in the National Evaluation Center for the Toxicology of Fertility Regulating Drugs (Center of GLP), mainly engaged in reproductive pharmacology and toxicology research and non-clinical safety evaluations on new drugs, especially investigations on reproductive toxicity mechanism.
       In addition to more than 30 pharma-toxicology research subjects presided over by her, she also principally participates in a major special project of science and technology known as “Creation of Major New Drugs” supported by the Ministry of Science and Technology (Establish a Pre-clinical Safety Evaluation Technical Platform up to International New Drug Research Specifications), takes in charge of contents construction for A Study on up-to-International-Specification Toxicological Test Methodology in Perinatal Stage, fulfills 2 youth fund projects of SIPPR and joins 9 ministerial and provincial subjects. Concerning awards that she wins, they are 1 third prize of the Science and Technology Progress Award of Shanghai, 1 second prize of the Science and Technology Award endowed by the Chinese Association for Laboratory Animal Sciences (CALAS). Moreover, she has published 24 papers and 4 monographs, namely, Commonly Used Experimental Animal Anatomy Pathol (as an associate editor), Atlas of Common Malformations in Laboratory Rabbit and Rat (as an associate editor), Prostate Pharmacology (as an editorial advisory board member) and Drug Reproductive and Developmental Toxicology (as an editorial advisory board member).
       As head of GLP Quality Assurance Department, she presides over and completes quality guarantee work for pre-clinical safety evaluations on 50 varieties of drugs to ensure that the item evaluated entirely conforms to GLP standards. Moreover, 6 varieties of drugs declared have acquired clinical production approvals of State Food and Drug Administration (SFDA) smoothly.